EMA's first public hearing: giving EU citizens a voice to help reduce the risk of valproate

View source ↗

Summary

EMA held its first public hearing to involve EU citizens in reducing the risk associated with valproate use, aiming to give patients a voice in safety decisions…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• Valproate (valproate)